Direct-to-consumer genotyping: are we ready for a brave new world?

[...] interpretation of results, particularly those associated with risk assessment, presymptomatic disorders, and right-to-know issues with at-risk family members, can be problematic. Some DTCG companies, such as Pathway Genomics, have a chief privacy officer and complex computer systems with state-of-the-art privacy protection, as well as computer programs that are frequently updated with the latest interpretations of testing results. Should individuals be free to request, from the privacy of their own homes and without any involvement of a healthcare professional, their own thyroid hormone levels, liver enzymes, prostatespecific antigen, and even serum troponin to determine if they have recently experienced a heart attack?